# Contact — the BPC-157 TB-500 editorial digest (Wolverine Doctor)

> Contact Wolverine Doctor, the independent editorial digest of the BPC-157 TB-500 literature. Editorial correspondence only — we do not provide medical advice, sell products, or fill prescriptions.

Editorial correspondence — corrections, citation questions, and source suggestions. Not a clinical or sales channel.

## What this channel is for

This is the editorial contact channel for the BPC-157 TB-500 digest. We welcome corrections, questions about a citation, and pointers to peer-reviewed studies or primary FDA records we should incorporate. If you believe a finding is misattributed to the wrong constituent — a TB-500 claim that actually rests on full-length Thymosin Beta-4, for instance — or a regulatory statement needs updating against the current FDA record, this is the right place to flag it.

We are particularly glad to receive new primary sources: a fresh systematic review, a published combination study should one ever appear, or an updated FDA listing decision after the scheduled PCAC evaluation. Accuracy on the constituent-versus-blend distinction is the whole point of this project, so a well-sourced correction is the most useful message we can get.

We read the [full reference list with PMIDs and DOIs](/references) as a living document and update it when the literature or the regulatory record moves.

## What this channel is not for

This project does not provide medical advice, diagnose, or recommend treatment. It does not sell, supply, or source any peptide, and it cannot direct you to a pharmacy, clinic, telehealth provider, or vendor. Questions about personal use, dosing, or how to obtain a substance cannot be answered here — those are clinical and regulatory matters outside an editorial digest's scope.

For the regulatory landscape, see the [Wolverine legal status and FDA 503A compounding access](/legal-status) page, which states the present-tense FDA record and cites it to source.

---

Two constituent channels read off one console — BPC-157 traced to its studies and TB-500 to its own, the repair-signal node where they converge left dark because no combination trial exists, and the FDA 503A and WADA marks posted before anything else; no clinic behind the readout and nothing here dispensed.